<h3>情人节促销 - 70% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) 发布了公告。</p>
<p>Hemogenyx Pharmaceuticals 从一组私人投资者那里通过直接认购筹集了 250 万英镑，发行了 333,333 股新股，每股价格为 7.50 英镑，并附带三年期的可行使认购权，行权价为 9 英镑，增加其已发行股本至 6,374,588 股。这笔资金将主要支持其 HG-CT-1 的 I 期临床试验的继续和剂量递增，该疗法用于成人和新近获批的儿童患者的复发或难治性急性髓性白血病，同时公司还通过将制造外包给 Made Scientific 来削减成本，并继续推进其 CDX 和 CBR 项目。</p>
<p>公司已获得独立数据安全监测委员会的积极推荐，允许在成人中进行下一个剂量水平，并获得美国 FDA 批准开始针对 12 至 18 岁患者的儿童 I 期试验，使 HG-CT-1 成为其主要价值驱动因素。管理层专注于通过运营效率降低烧钱率，包括外部制造转移，并表示将在适当时候报告其更广泛管道的进展，预计新资本和配售股份的入场将增强其财务基础和市场存在感。</p>
<p>对 (GB:HEMO) 股票的最新分析师评级为持有，目标价为 725.00 英镑。要查看 HemoGenyx Pharmaceuticals Plc 股票的完整分析师预测列表，请参见 GB:HEMO 股票预测页面。</p>
<p><strong>Spark 对 GB:HEMO 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的 AI 分析师，GB:HEMO 的评级为中性。</p>
<p>该评分主要受到非常疲弱的财务表现（无收入、持续亏损和现金消耗，以及因股本减少和杠杆增加而带来的更高资产负债表风险）的影响。技术面提供了一些抵消，近期动能强劲，但超买指标增加了短期风险，且由于负市盈率和无股息收益，估值支持有限。</p>
<p>要查看 Spark 对 GB:HEMO 股票的完整报告，请点击这里。</p>
<p><strong>关于 HemoGenyx Pharmaceuticals Plc 的更多信息</strong></p>
<p>Hemogenyx Pharmaceuticals plc 是一家临床阶段的生物制药公司，上市于伦敦证券交易所，总部位于伦敦，在纽约市设有运营子公司。该公司开发针对血液和自身免疫疾病的新型药物和治疗，围绕多个互补的产品候选者和创新药物开发平台技术。</p>
<p><strong>平均交易量：</strong> 44,007</p>
<p><strong>技术情绪信号：</strong> 强烈买入</p>
<p><strong>当前市值：</strong> 6645 万英镑</p>
<p>要全面评估 HEMO 股票，请访问 TipRanks 的股票分析页面。</p>

HEPA

426CVR015TMP

<p>HemoGenyx Pharmaceuticals 通过直接认购新股从私人投资者那里筹集了 250 万英镑，资金将用于其 HG-CT-1 的 I 期临床试验，这是一种针对急性髓性白血病的 CAR-T 疗法。该公司已获得 FDA 对儿童试验的批准，并计划通过外包生产来降低成本。尽管持续亏损和现金消耗，分析师对该股票的评级为持有，目标价格为 725.00 英镑，而 Spark 的 AI 分析师由于财务表现疲弱和高资产负债表风险给予其中性评分</p>

<h3>Valentine's Day Sale - 70% Off</h3>
<div class="lb-trans"><h3>情人节促销 - 70% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an announcement.</p>
<div class="lb-trans"><p>HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) 发布了公告。</p>
</div><p>Hemogenyx Pharmaceuticals has raised £2.5 million from a consortium of private investors via a direct subscription for 333,333 new shares at £7.50 each, alongside three-year warrants exercisable at £9, increasing its issued share capital to 6,374,588 shares. The funding will primarily support the continuation and dose escalation of its Phase I clinical trials for HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia in adults and newly cleared pediatric patients, while the company also cuts costs by outsourcing manufacturing to Made Scientific and continues to advance its CDX and CBR programmes.</p>
<div class="lb-trans"><p>Hemogenyx Pharmaceuticals 从一组私人投资者那里通过直接认购筹集了 250 万英镑，发行了 333,333 股新股，每股价格为 7.50 英镑，并附带三年期的可行使认购权，行权价为 9 英镑，增加其已发行股本至 6,374,588 股。这笔资金将主要支持其 HG-CT-1 的 I 期临床试验的继续和剂量递增，该疗法用于成人和新近获批的儿童患者的复发或难治性急性髓性白血病，同时公司还通过将制造外包给 Made Scientific 来削减成本，并继续推进其 CDX 和 CBR 项目。</p>
</div><p>The company has received a positive recommendation from the independent Data Safety Monitoring Board to proceed to the next dose level in adults and secured U.S. FDA clearance to begin a pediatric Phase I trial for patients aged 12–18, positioning HG-CT-1 as its lead value driver. Management has focused on reducing burn rate through operational efficiencies, including the external manufacturing transfer, and maintains that progress on its broader pipeline will be reported in due course, with the new capital and admission of the placing shares expected to reinforce its financial footing and market presence.</p>
<div class="lb-trans"><p>公司已获得独立数据安全监测委员会的积极推荐，允许在成人中进行下一个剂量水平，并获得美国 FDA 批准开始针对 12 至 18 岁患者的儿童 I 期试验，使 HG-CT-1 成为其主要价值驱动因素。管理层专注于通过运营效率降低烧钱率，包括外部制造转移，并表示将在适当时候报告其更广泛管道的进展，预计新资本和配售股份的入场将增强其财务基础和市场存在感。</p>
</div><p>The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.</p>
<div class="lb-trans"><p>对 (GB:HEMO) 股票的最新分析师评级为持有，目标价为 725.00 英镑。要查看 HemoGenyx Pharmaceuticals Plc 股票的完整分析师预测列表，请参见 GB:HEMO 股票预测页面。</p>
</div><p><strong>Spark’s Take on GB:HEMO Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 GB:HEMO 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, GB:HEMO is a Neutral.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的 AI 分析师，GB:HEMO 的评级为中性。</p>
</div><p>The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.</p>
<div class="lb-trans"><p>该评分主要受到非常疲弱的财务表现（无收入、持续亏损和现金消耗，以及因股本减少和杠杆增加而带来的更高资产负债表风险）的影响。技术面提供了一些抵消，近期动能强劲，但超买指标增加了短期风险，且由于负市盈率和无股息收益，估值支持有限。</p>
</div><p>To see Spark’s full report on GB:HEMO stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 对 GB:HEMO 股票的完整报告，请点击这里。</p>
</div><p><strong>More about HemoGenyx Pharmaceuticals Plc</strong></p>
<div class="lb-trans"><p><strong>关于 HemoGenyx Pharmaceuticals Plc 的更多信息</strong></p>
</div><p>Hemogenyx Pharmaceuticals plc is a clinical-stage biopharmaceutical company listed on the London Stock Exchange and headquartered in London, with operating subsidiaries in New York City. The company develops novel medicines and treatments for blood and autoimmune diseases, built around several complementary product candidates and platform technologies for innovative drug development.</p>
<div class="lb-trans"><p>Hemogenyx Pharmaceuticals plc 是一家临床阶段的生物制药公司，上市于伦敦证券交易所，总部位于伦敦，在纽约市设有运营子公司。该公司开发针对血液和自身免疫疾病的新型药物和治疗，围绕多个互补的产品候选者和创新药物开发平台技术。</p>
</div><p><strong>Average Trading Volume:</strong> 44,007</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 44,007</p>
</div><p><strong>Technical Sentiment Signal:</strong> Strong Buy</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 强烈买入</p>
</div><p><strong>Current Market Cap:</strong> £66.45M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 6645 万英镑</p>
</div><p>For a thorough assessment of HEMO stock, go to TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>要全面评估 HEMO 股票，请访问 TipRanks 的股票分析页面。</p>
</div>

Hemogenyx 筹集 250 万英镑以推进成人和儿童急性髓性白血病（AML）的 CAR-T 试验